Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06953622
Recruiting Observational

Establishment of a Clinical and Prognostic Follow-up Cohort of Migraine Patients With Patent Foramen Ovale

NCT06953622 · tracked via the Priya Life Science China tracker
Sponsor
Peking University Third Hospital
Phase
Observational
Started
2024-01-01
Last updated
2025-05-01

Condition(s) studied

MigrainePatent Foramen Ovale

Investigational drug(s) / intervention(s)

Conservative treatmentAntipaletet drugPatent Foramen Ovale Closure

Conservative treatment: Receive no antipaletet drug treatment and surgery

Antipaletet drug: Use of antipaletet drugs.

Patent Foramen Ovale Closure: Receive the surgery of Patent Foramen Ovale

Study summary

To establish a headache center in China that combines clinical, imaging and laboratory examinations, explore the feasible treatment options for migraine combined with patent foramen ovale, and search for the possible influencing factors, construct models that influence prognosis.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Meet the diagnostic criteria for migraine in the International Classification of Headache (ICHD-3); * Confirmation of patent foramen ovale through transthoracic echocardiography(TTE) or transesophageal echocardiography(TEE)/right heart contrast echocardiography * Agree to participate in the study and sign the informed consent form. Exclusion Criteria: * Can not sign the informed consent form or cooperate with follow-up.

Primary outcome measure(s)

  • The changes of migraine attacks — 3 months, 6 months, 1 year, 2 years and 3 years
    Migraine attacks are an important indicator of improvement in symptoms. The comparison measures included headache frequency, duration, pain degree, VAS scores, HIT-6 scores, HAMA, HAMD, and PSQI.

Trial sites (1)

FacilityCityRegionStatus
Peking University Third Hospital Beijing China Recruiting

More Peking University Third Hospital trials in China

Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease Recruiting
A Study on Diagnosis and Treatment Strategies for Atlantoaxial Dislocation Recruiting
LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer Enrolling by invitation
Prospective Cohort Study on Refractory Rheumatoid Arthritis Recruiting
Multi-Agent Collaborative ADR Prediction With Human-Machine Decision Comparison Recruiting

Other trials for the same condition

Multicenter, Double-blind, and Randomized Controlled Trial of Ultra-Distal TENS Device for Migraine Treatment Active, not recruiting
Effectiveness of Auricular Acupuncture for Migraine Starting soon
Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Knee Osteoarthritis(OA) Recruiting
Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine Active, not recruiting
Desvenlafaxine for Preventive Treatment of Frequent Migraines Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06953622 on ClinicalTrials.gov ↗ ← All trials in China